Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Lancet
    February 2026
  1. LEJEUNE CL, Van Calsteren K, Baert T, Vandecaveye V, et al
    A multidisciplinary management approach to cervical cancer during pregnancy.
    Lancet. 2026 Feb 17:S0140-6736(26)00190-X. doi: 10.1016/S0140-6736(26)00190.
    >> Share

    January 2026
  2. RAY-COQUARD I, Wilson C, Moore K
    The Lancet Commission on Ovarian Cancer: towards equity-driven reform.
    Lancet. 2026 Jan 8:S0140-6736(25)02463-8. doi: 10.1016/S0140-6736(25)02463.
    >> Share

  3. ROBERTS I
    Uterine atony and anaemia in postpartum haemorrhage.
    Lancet. 2026;407:29.
    >> Share

  4. YUNAS I, Devall A, Coomarasamy A
    Uterine atony and anaemia in postpartum haemorrhage - Authors' reply.
    Lancet. 2026;407:29-30.
    >> Share

  5. MANSUKHANI R, Chaudhri R, Bello FA, Muganyizi P, et al
    Uterine atony and anaemia in postpartum haemorrhage.
    Lancet. 2026;407:28-29.
    >> Share

    December 2025
  6. NASH Z, Christmas M, Gronlund T, Hickey M, et al
    Top ten menopause research priorities.
    Lancet. 2025;404:2535-2536.
    >> Share

  7. UBOM AE, Oiwoh SO
    Fetal and maternal outcomes following mpox infection in pregnancy.
    Lancet. 2025 Dec 19:S0140-6736(25)02317-7. doi: 10.1016/S0140-6736(25)02317.
    >> Share

  8. VAKANIAKI EH, Barhishindi I, Mubiala A, Malembaka EB, et al
    Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.
    Lancet. 2025 Dec 19:S0140-6736(25)02309-8. doi: 10.1016/S0140-6736(25)02309.
    >> Share

  9. MOAYAD L, Mihan A, Peters SAE, Van Spall HGC, et al
    Inclusion of women who are pregnant, lactating, or of reproductive potential in clinical trials: health, ethical, and regulatory considerations.
    Lancet. 2025;406:2858-2864.
    >> Share

  10. TONG S, Cluver CA, Walker SP
    Reducing term pre-eclampsia by 30%: is it possible?
    Lancet. 2025 Dec 4:S0140-6736(25)01672-1. doi: 10.1016/S0140-6736(25)01672.
    >> Share

  11. GOADSBY J, Syngelaki A, Magee LA, von Dadelszen P, et al
    Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.
    Lancet. 2025 Dec 4:S0140-6736(25)01207-3. doi: 10.1016/S0140-6736(25)01207.
    >> Share

    November 2025
  12. NANA M, Painter R, Williamson C, Nelson-Piercy C, et al
    Hyperemesis gravidarum.
    Lancet. 2025 Nov 13:S0140-6736(25)01454-0. doi: 10.1016/S0140-6736(25)01454.
    >> Share

  13. ANDERSON DJ, Bearak JM, Grimstad FW, Palanee-Phillips T, et al
    Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health.
    Lancet. 2025;406:2119-2132.
    >> Share

    October 2025
  14. SURYAWANSHI H, Gemmell LC, Morgan S, Koustas G, et al
    First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia.
    Lancet. 2025 Oct 31:S0140-6736(25)01623-X. doi: 10.1016/S0140-6736(25)01623.
    >> Share

  15. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
    Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
    Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
    >> Share

  16. BEKKER LG, Joseph Davey D, Saidi F
    Two for two: lenacapavir during pregnancy and lactation.
    Lancet. 2025;406:1560-1561.
    >> Share

    August 2025
  17. MCCORMACK M, Eminowicz G, Vaja S, Hackshaw A, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.
    Lancet. 2025;406:807.
    >> Share

  18. PETRIC P, Lindegaard JC, Schmid MP, Jurgenliemk-Schulz I, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation.
    Lancet. 2025;406:806-807.
    >> Share


  19. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    >> Share

  20. LIU T, Lu D, Wu X
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.
    Lancet. 2025;406:446.
    >> Share

  21. CHENG C
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445.
    >> Share

  22. HUANG L, We Y, Chen F
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445-446.
    >> Share

    July 2025
  23. BRASIL P, Nielsen-Saines K, Guaraldo L, Fuller T, et al
    A decade later, what have we learned from the Zika epidemic in children with intrauterine exposure?
    Lancet. 2025 Jul 3:S0140-6736(25)00826-8. doi: 10.1016/S0140-6736(25)00826.
    >> Share

    June 2025
  24. HARTER P, Marme F
    Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancer.
    Lancet. 2025;405:2180-2182.
    >> Share

  25. DE SMIT NS, de Lange ME, Boomsma MF, Huirne JAF, et al
    Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas.
    Lancet. 2025 Jun 19:S0140-6736(25)00728-7. doi: 10.1016/S0140-6736(25)00728.
    >> Share

  26. FERNANDEZ TURIENZO C, November L, Kamara M, Conteh O, et al
    Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.
    Lancet. 2025 Jun 18:S0140-6736(25)00454-4. doi: 10.1016/S0140-6736(25)00454.
    >> Share

  27. HODNETT E
    A community-based landmark trial to save the lives of pregnant adolescents and their newborns in sub-Saharan Africa.
    Lancet. 2025 Jun 18:S0140-6736(25)00731-7. doi: 10.1016/S0140-6736(25)00731.
    >> Share

  28. OLAWAIYE AB, Gladieff L, O'Malley DM, Kim JW, et al
    Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
    Lancet. 2025 Jun 2:S0140-6736(25)01040-2. doi: 10.1016/S0140-6736(25)01040.
    >> Share

    May 2025
  29. SCHOENAKER D, Stephenson J, Chakrabarti S, Alloway L, et al
    Prioritising maternal health must include care before pregnancy.
    Lancet. 2025;405:1903.
    >> Share

  30. GARDOSI J, Ewington LJ, Booth K, Bick D, et al
    Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
    Lancet. 2025 May 1:S0140-6736(25)00162-X. doi: 10.1016/S0140-6736(25)00162.
    >> Share

    March 2025
  31. LAUDANSKI P
    Natural or artificial menstrual cycle for frozen embryo transfer.
    Lancet. 2025;405:893-894.
    >> Share

  32. MAKAMA M, Vogel JP
    Atosiban and managing women in preterm labour.
    Lancet. 2025 Mar 3:S0140-6736(25)00402-7. doi: 10.1016/S0140-6736(25)00402.
    >> Share

    February 2025
  33. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    >> Share

  34. HUGHES H
    Endometriosis: an Australian perspective on encouraging change.
    Lancet. 2025;405:378-379.
    >> Share

  35. DANG L, Mi M, Qiao Y, Zhu L, et al
    Eliminating cervical cancer in the Tibetan Plateau.
    Lancet. 2025;405:375-376.
    >> Share

    November 2024
  36. LORUSSO D, Yamada K, Li K, Cerrotta A, et al
    Pembrolizumab for locally advanced cervical cancer - Authors' reply.
    Lancet. 2024;404:2051-2052.
    >> Share

  37. DONG B, Lu Y, Wang Y, Sun P, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050.
    >> Share

  38. SCHMID MP, Petric P, Mahantshetty U, Kirisits C, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050-2051.
    >> Share

  39. KAMRAVA M, Beriwal S
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049.
    >> Share

  40. MURAKAMI N, Okonogi N, Terao Y, Shikama N, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049-2050.
    >> Share


  41. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    >> Share

    October 2024
  42. MCCORMACK M, Eminowicz G, Gallardo D, Diez P, et al
    Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    Lancet. 2024;404:1525-1535.
    >> Share

  43. DUSKA LR, Randall LM
    Progress in the treatment paradigms for locally advanced cervical cancer.
    Lancet. 2024;404:1494-1496.
    >> Share

  44. WU X, Sun Y, Yang H, Wang J, et al
    Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
    Lancet. 2024 Oct 15:S0140-6736(24)02135-4. doi: 10.1016/S0140-6736(24)02135.
    >> Share

  45. SUN C, Ma D
    Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2024 Oct 15:S0140-6736(24)02196-2. doi: 10.1016/S0140-6736(24)02196.
    >> Share

  46. THE LANCET
    Endometriosis: addressing the roots of slow progress.
    Lancet. 2024;404:1279.
    >> Share

    September 2024
  47. SHARP G, Randhawa A, Fernando AN
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01710-0. doi: 10.1016/S0140-6736(24)01710.
    >> Share

  48. BROWN L, Hunter MS, Crandall CJ, Connors HJ, et al
    Reflections on The Lancet menopause Series - Authors' reply.
    Lancet. 2024 Sep 25:S0140-6736(24)01712-4. doi: 10.1016/S0140-6736(24)01712.
    >> Share

  49. STUCKEY BGA
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01709-4. doi: 10.1016/S0140-6736(24)01709.
    >> Share

  50. XIAO Y, Shen M, Chen X
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01711-2. doi: 10.1016/S0140-6736(24)01711.
    >> Share

  51. GENNIGENS C
    Hope emerging in the locally advanced cervical cancer landscape.
    Lancet. 2024 Sep 13:S0140-6736(24)01918-4. doi: 10.1016/S0140-6736(24)01918.
    >> Share

  52. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-
    Lancet. 2024 Sep 13:S0140-6736(24)01808-7. doi: 10.1016/S0140-6736(24)01808.
    >> Share

    August 2024
  53. RYDELIUS J, Hognert H, Kopp-Kallner H, Brandell K, et al
    First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024;404:864-873.
    >> Share

  54. MOSESON H, Gerdts C
    Expanding access, reducing burdens, and improving person-centred care in abortion.
    Lancet. 2024;404:826-827.
    >> Share

  55. FIGUERAS F, Rial-Crestelo M, Gratacos E
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
    Lancet. 2024;404:751-752.
    >> Share

  56. GILES-CLARK HJ, Rolnik DL, Hodges RJ, Skinner SM, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750.
    >> Share

  57. BACON I, Hezelgrave NL, Cerdeira AS, Mylrea-Foley B, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750-751.
    >> Share

  58. KAMIHARA Y, Nagase H, Ishikawa H
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749-750.
    >> Share

  59. MEIJERINK L, Terstappen F, Depmann M, Bekker M, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749.
    >> Share

  60. BORNSTEIN E, Vintzileos A
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:748-749.
    >> Share

  61. WEI F, Georges D, Man I, Baussano I, et al
    Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
    Lancet. 2024;404:435-444.
    >> Share

  62. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    >> Share

    July 2024
  63. ALVES L
    New abortion bill in Brazil sparks backlash.
    Lancet. 2024;404:17.
    >> Share

    June 2024
  64. HO VNA, Pham TD, Nguyen NT, Wang R, et al
    Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
    Lancet. 2024 Jun 26:S0140-6736(24)00756-6. doi: 10.1016/S0140-6736(24)00756.
    >> Share

  65. JAFFE S
    US Supreme Court protects access to abortion medication.
    Lancet. 2024;403:2679-2680.
    >> Share

  66. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    >> Share

  67. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    >> Share

    May 2024
  68. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    >> Share

  69. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    >> Share

    April 2024
  70. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
    Vitamin B12 deficiency in pregnant women - Authors' reply.
    Lancet. 2024;403:1450.
    >> Share

  71. SEN S
    Vitamin B12 deficiency in pregnant women.
    Lancet. 2024;403:1449-1450.
    >> Share

    March 2024
  72. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    >> Share

  73. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    >> Share

  74. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
    Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
    >> Share

  75. TEWARI KS, Monk BJ
    Immunotherapy plus chemoradiotherapy in cervical cancer management.
    Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
    >> Share

  76. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
    US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
    Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
    >> Share

  77. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
    Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
    Lancet. 2024;403:1081-1082.
    >> Share

  78. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
    Optimising health after early menopause.
    Lancet. 2024;403:958-968.
    >> Share

  79. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

  80. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    >> Share

  81. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    >> Share

  82. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    >> Share

  83. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    >> Share

  84. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    >> Share

  85. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    >> Share

  86. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016